Transplacental Transmission of Serotype-Specific Pneumococcal Antibodies in a Brazilian Population

BEATRIZ T. COSTA CARVALHO,1* MAGDA M. CARNEIRO-SAMPAIO,2 DIRCEU SOLE,1 CHARLES NASPITZ,1 LILY E. LEIVA, 3 AND RICARDO U. SORENSEN3

Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, UNIFESP-EPM,1 and Department of Immunology, Instituto de Ciências Biomédicas, Universidade de São Paulo.2 São Paulo, Brazil, and Department of Pediatrics, Louisiana State University Medical Center, New Orleans, Louisiana3

Received 6 April 1998/Returned for modification 15 June 1998/Accepted 2 October 1998

The highest incidence of severe pneumococcal infections in children occurs in the first 6 months of life; however, immunization of infants with the existing polysaccharide vaccines is ineffective. We wished to determine the prevalence of immunoglobulin G (IgG) pneumococcal antibodies in unimmunized Brazilian mothers and their transplacental transmission to term and preterm infants. Total IgG, IgG1 and -2 subclass levels, and IgG antibodies against Streptococcus pneumoniae serotypes 1, 3, 6B, 9V, and 14 were determined in 15 pairs of mothers and term newborns (gestational age, ≥37 weeks) and in 18 pairs of mothers and preterm newborns (gestational age, 32 to 36 weeks). Serotype-specific anti-pneumococcal antibodies were detected by a recently standardized enzyme-linked immunosorbent assay calibrated with the 89-SF reference serum. Varying percentages of the mothers had antibody concentrations below arbitrarily defined protective levels: 33% for serotype 1, 67% for serotype 3, 30% for serotype 6B, 52% for serotype 9V, and 22% for serotype 14. In term newborns, IgG1 concentrations were slightly higher than maternal concentrations; in preterm newborns, the concentrations were much lower. Concentrations of IgG2 in term and preterm infants were significantly lower than in the mothers. Transplacental transmission of antibodies to serotypes 3 and 14 was clearly different from that of antibodies to serotypes 1, 6B, and 9V. Concentrations of IgG antibodies against serotypes 3 and 14 were similar to or higher than those of the mothers; against serotypes 1, 6B, and 9V they ranged from 77 to 83% of maternal concentrations in term newborns and also in preterm infants, although transplacental transmission of antibodies was proportionally lower for each specific serotype in preterm than in term infants. These data are relevant for developing strategies to protect infants against pneumococcal infections in the first months of life. Our findings and a review of existing information stress the importance of understanding the relationships among pneumococcal immunization, IgG subclass antibodies to individual serotypes, transplacental transport, half-life, and antibody function and their protective values against infection.

Pneumococcal infections cause high morbidity and mortality in children during the first 2 years of life, with the highest incidence of severe, systemic pneumococcal infections occurring in the first year of life (15, 18). Immunization of infants with the existing polysaccharide vaccines, however, becomes effective only after 2 years of age. Conjugate pneumococcal vaccines containing five or seven polysaccharides have been found to be immunogenic in the first year of life in several studies (1, 3, 31). However, these vaccines are still experimental and the small number of serotype polysaccharides included in the vaccines may limit the coverage they offer. A 10-year study of 308 cases of meningitis in children under 2 years of age in São Paulo, Brazil (48), reveals that vaccine formula B, which includes serotypes 1, 5, 6B, 14, 18C, 19F, and 23F (47), would cover only 68% of the infections caused by 42 different strains, even taking into account the cross-reactivity of vaccine and nonvaccine serotypes (41). Two recent studies in Brazil estimate that the 23-valent polysaccharide vaccine offers protection against 85.7 and 89.6% of these infections, respectively, if vaccine-related cross-reactive serotypes are taken into account (11, 44).

The diversity of serotypes causing invasive infections in Brazil, the limitations affecting the development of conjugated vaccines to multiple serotypes, and the cost of a single polysaccharide conjugate vaccine (28) led us to explore other avenues for protecting infants against pneumococcal infections. One of these strategies is the immunization of mothers to provide passive immunization to infants (45).

As a preliminary step in evaluating the possibility of increasing infant protection against invasive pneumococcal infections through maternal immunization, we determined the presence of pneumococcal immunoglobulin G (IgG) antibodies in an unimmunized population of Brazilian mothers and studied the transplacental transmission of these antibodies in term and preterm deliveries.

MATERIALS AND METHODS

Population. The study involved 33 mother-child pairs. All mothers were well nourished. None of the mothers had been immunized with a pneumococcal vaccine. Gestational age was estimated by a neonatologist based on a somatic and neurological examination (12). Fifteen mothers (age range, 18 to 38 years) had term pregnancies (≥37 weeks); 18 mothers (age range, 18 to 37 years) had preterm pregnancies (32 to 36 weeks). After informed consent was obtained, blood samples were collected from the mothers at the time of delivery and from the umbilical cords of their infants. The serum was frozen at −20°C until analysis. All mother-infant pairs were analyzed simultaneously.

IgG subclass determinations. IgG subclass concentrations (in milligrams per deciliter) were measured by the single radial immunodiffusion technique with the following specific monoclonal antibodies: clone JL512 for IgG1 and clone GOM1 for IgG2 (Unipath, Hampshire, United Kingdom) (20). The results were calibrated with the standard serum WHO 67/97, and secondary controls were kindly provided by Lars A. Hanson, Göteborg University, Sweden.

Pneumococcal polysaccharide antibody assay. Using a modified enzyme-linked immunosorbent assay (ELISA) protocol (25, 40), we measured IgG an-
TABLE 1. Transplacental transmission of IgG1 and IgG2 in preterm and term pregnancies

| Parameter | Term (n = 15) | Preterm (n = 18) |
|-----------|--------------|-----------------|
|           | IgG1         | IgG2            | IgG1            | IgG2            |
| GM* (CI)  |              |                 |                 |                 |
| Mothers   | 758 (640–1,017) | 164 (134–236)  | 751 (650–960)  | 168 (144–218)  |
| Newborns  | 852 (764–993)  | 112 (86–180)   | 423 (360–594)  | 83 (74–96)     |
| Ratio     | 112 (95–145)   | 68 (56–99)    | 58 (50–77)     | 47 (41–62)     |
| r         | 0.4976        | 0.6077         | 0.4224         | 0.0849         |
| Correlation P value | 0.0591 | 0.0163 | 0.0912 | 0.7460 |

a GM, geometric mean.

All mothers studied had IgG subclass concentrations within the normal limits established for the Brazilian population (Table 1). The concentrations of IgG1 in term newborns were similar to the maternal concentrations (P = 0.4631), while the concentrations in preterm newborns were significantly lower than those in the mothers (P = 0.0019). The concentration of IgG2 in term infants was significantly lower than in the mothers (P = 0.0302), with an even larger difference between maternal and newborn concentrations in preterm pregnancies (P = 0.0006).

The geometric mean maternal pneumococcal antibody concentration (in micrograms per milliliter) varied for the five serotypes studied: serotype 1, 1.54 (95% CI, 1.50 to 2.89); serotype 3, 0.96 (95% CI, 0.81 to 2.67); serotype 6B, 1.96 (95% CI, 1.95 to 2.67); serotype 9V, 1.13 (95% CI, 1.19 to 2.52); and serotype 14, 2.93 (95% CI, 2.49 to 6.32). A detailed analysis of the distribution of maternal antibody concentrations reveals varying percentages of mothers in arbitrarily-defined groups (Fig. 1). Concentrations of antibodies against the different serotypes of ≤1.2 μg/ml were found in 22 to 67% of the unimmunized mothers studied: 33% for serotype 1, 67% for serotype 3, 30% for serotype 6B, 52% for serotype 9V, and 22% for serotype 14.

In term newborns, concentrations of serotype-specific IgG antibodies against serotypes 3 and 14 were similar to or higher than those of the mothers (Table 2); however, the mean percentage of transmission of antibodies against serotype 1, 6B, and 9V ranged from 77 to 83%. A difference in the transplacental transmission between serotypes 3 and 14 and serotypes 1, 6B, and 9V was also noted in preterm infants (Table 3). The ratios of transplacental transmission were lower for preterm newborns than for term newborns for each of the serotypes studied (Tables 2 and 3). There was a significant correlation between maternal and infant antibody concentrations for both term and preterm infants (Tables 2 and 3). There was no difference between the transplacental transmissions of high and low maternal antibody concentrations (data not shown).

There was no correlation between serotype-specific antibody concentrations and IgG1 or IgG2 subclass concentrations in either the mothers or the newborns or between the ratios of

![FIG. 1. Distribution of concentrations of pneumococcal antibodies against five serotypes in 33 unimmunized Brazilian women.](image-url)
transplacental transmission of specific antibodies and IgG subclasses (data not shown).

**DISCUSSION**

All serotypes included in this study can cause invasive disease in infants (11, 23, 44, 48). Four of these serotypes are included in the new experimental conjugate vaccines proposed for different areas of the world (47). This study was performed with unimmunized Brazilian women. Immunization with a 23-valent polysaccharide vaccine is likely to increase serotype-specific antibody concentrations. Maternal immunization during pregnancy was shown to significantly increase the geometric mean titers against serotypes 6B and 19F in one study in Bangladesh (45) and to five of six serotypes tested in The Gambia (38). Since the serotypes tested in these studies are no more immunogenic than other serotypes included in the 23-valent vaccine, antibody concentrations to other serotypes are also likely to increase after immunization.

There was a significant correlation between maternal and newborn antibodies for all serotypes in both term and preterm pregnancies. The ratios of transplacental transmission, however, followed two distinct patterns, one similar to the transmission of total IgG1 for serotypes 3 and 14 and another similar to the transmission of IgG2 for serotypes 1, 6B, and 9V. In some studies, transplacental transmission of IgG2 has been found to be less efficient than that of other IgG subclasses (9, 14, 22), probably due to the low binding ability of placental immunoglobulin receptors for IgG2 (35). Other studies of transplacental transmission have established low ratios for antibodies to serotype 7F (0.63) (13), for antibodies to native type III group B streptococcal polysaccharide (5), and for anti- group A streptococcal polysaccharide antibodies (16). Our results showing different ratios for serotypes 6B and 14 are in agreement with those of Anderson et al., who found much lower transmission ratios for antibodies to serotype 6A (0.54) than for serotype 14 (0.89) (4). Earlier studies measuring both IgM and IgG antibodies had shown transmission ratios lower than 50% for several serotypes (21); however, only IgG antibodies are transmitted transplacentally and measured in cord blood.

The predominant isotype of pneumococcal IgG antibodies is IgG2 (7, 33, 34, 46). However, anti-pneumococcal serum antibodies have also been found in all other IgG subclasses (6). The preponderance of IgG2 subclass antibodies may be more pronounced in older individuals than in children (19, 33) and may also be more pronounced in the responses to certain serotypes (19). To what extent immunization may alter the isotype and therefore the transplacental transmission pattern for each serotype-specific antibody has yet to be determined. Conjugate *Haemophilus influenzae* type b vaccines administered during the last trimester of pregnancy resulted in significantly higher PRP antibodies in infants at birth and at 2 months of age than did polysaccharide vaccine (17), suggesting that the immunization of women with conjugate pneumococcal vaccines should be considered in the future.

After transplacental transmission, the half-life of anti-pneumococcal antibodies has been estimated at 35 days (45); the

| Parameter | Value in serotype: |
|-----------|-------------------|
| 1 (n = 15) | 3 (n = 15) | 6B (n = 15) | 9V (n = 15) | 14 (n = 14) |
| Mothers | | | | |
| GM (µg/ml) | 1.73 | 0.94 | 2.09 | 1.30 | 3.21 |
| 95% CI | 1.28–4.14 | 0.44–2.48 | 1.63–5.00 | 0.92–3.44 | 1.95–6.98 |
| Infants | | | | |
| GM (µg/ml) | 1.38 | 1.03 | 1.60 | 0.98 | 3.09 |
| 95% CI | 0.87–3.53 | 0.17–3.25 | 0.99–4.00 | 0.63–2.59 | 2.24–5.76 |
| P value | 0.0151 | 0.5995 | 0.0031 | 0.0012 | 0.9515 |
| Ratio (mean % ± SD) | 83 ± 23 | 116 ± 44 | 79 ± 20 | 77 ± 18 | 99 ± 24 |

| Parameter | Value in serotype: |
|-----------|-------------------|
| 1 (n = 18) | 3 (n = 18) | 6B (n = 18) | 9V (n = 18) | 14 (n = 9) |
| Mothers | | | | |
| GM (µg/ml) | 1.40 | 0.98 | 1.87 | 1.01 | 2.34 |
| 95% CI | 1.18–2.34 | 0.41–3.55 | 1.41–3.61 | 0.84–2.33 | 0.61–8.02 |
| Infants | | | | |
| GM (µg/ml) | 0.70 | 0.69 | 0.82 | 0.52 | 1.82 |
| 95% CI | 0.54–1.22 | 0.35–2.02 | 0.64–1.53 | 0.40–1.18 | 0.78–4.67 |
| P value | 0.0007 | 0.4376 | 0.0007 | 0.0007 | 0.0977 |
| Ratio (Mean % ± SD) | 58 ± 32 | 94 ± 69 | 53 ± 30 | 61 ± 34 | 86 ± 44 |
| r | 0.837 | 0.551 | 0.693 | 0.849 | 0.963 |
| P value | <0.0001 | 0.0179 | 0.0014 | <0.0001 | <0.0001 |

*GM, geometric mean.*

**TABLE 2. Transplacental transmission of pneumococcal serotype antibodies in term newborns**

**TABLE 3. Transplacental transmission of pneumococcal serotype antibodies in preterm newborns**
half-life is approximately 30 days after passive administration of intravenous IgG to patients with antibody deficiency syndromes (43). This half-life may be affected by the IgG subclass to which the antibodies belong (36).

Transplacental transmission of high maternal antibody concentrations may permit the postponement of infant immunization, which would allow a maturation of the response to protein-polysaccharide conjugates, possibly through enhanced priming for the protein carrier function by diphtheria, pertussis, and tetanus immunization (39). This may be particularly important for preterm infants, whose response to the first doses of a conjugate *H. influenzae* vaccine was found to be significantly lower than that of older infants (26). The risk of high concentrations of anti-polysaccharide antibodies interfering with the response to immunization with conjugate vaccines is negligible or nonexistent (27, 32).

Antibody concentrations needed for the protection of infants against invasive pneumococcal disease have not yet been defined with the ELISA employed in our study. Antibody concentrations of ≥200 ng/ml were correlated with protection against sepsis in adults and with decreased nasopharyngeal colonization with specific pneumococcal serotypes in children (29, 30). This antibody concentration is approximately equivalent to a concentration of 1.3 μg/ml measured by the ELISA (21a). According to our results, few infants born to unimmunized mothers in Brazil would have antibody concentrations sufficient to offer protection. However, these results will have to be reinterpreted once a better definition of protective concentrations of antibodies against the various *S. pneumoniae* serotypes has been formulated.

The evaluation of opsonic activity may also allow the assessment of the protection conferred by transplacently transmitted antibodies. A correlation between the measurement of opsonic activity in vitro and protection against infection has been established for mice (2). In one study of humans, no correlation was found between opsonization and antibody levels in unimmunized adults. After immunization, most sera had increased antibody titers and opsonic activity, but a lack of correlation persisted for individual sera (37). In another study, IgG2 antibodies correlated better with opsonic activity than IgG1 antibodies (24). Recently, we have shown that immunization with a conjugate heptavalent pneumococcal vaccine increases opsonophagocytic activity to some vaccine serotypes (42). We are now extending these studies of opsonophagocytosis to mothers and infants followed during the first year of life.

We conclude that a relatively high percentage of this study population of unimmunized Brazilian mothers have low antibody concentrations against several pneumococcal serotypes. These data are relevant for future strategies for protection against pneumococcal infections in the first months of life. Immunization of pregnant women in high-risk groups may protect both the mother and the infant. Our findings and a review of existing information stress the importance of future studies to clarify the relationships among pneumococcal immunization, IgG subclass antibodies to individual serotypes, transplacental transport, half-life, and antibody function and their protective values against infection.

ACKNOWLEDGMENTS

This research was supported in part by an unrestricted grant from Lederle-Praxis Biologics and by FAPESP (Fundação de Amparo a Pesquisa do Estado de São Paulo).

REFERENCES

1. Ahman, H., K. Haythty, P. Tammimen, A. Vuorela, F. Malinowski, and J. Eskola. 1996. Pentavalent pneumococcal oligosaccharide conjugate vaccine

PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr. Infect. Dis. J. 15:834–139.

2. Alonso De Velasco, E., A. T. Dekker, A. F. Verhul, R. G. Feldman, J. Verhoeft, and H. Niemcke. 1995. Anti-polysaccharide immunoglobulin isotypes and opsonic activity of antisera: interaction with protection against *Streptococcus pneumoniae* infections in mice. J. Infect. Dis. 172:562–565.

3. Anderson, E. L., D. J. Kennedy, K. M. Goldmacher, J. Donnelly, and P. M. Mendelman. 1996. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr. 128:549–653.

4. Anderson, P. S., P. Porcelli, and M. Pichichero. 1992. Natural maternal and cord serum antibodies to pneumococcal serotypes 6A, 14, 19F and 23F polysaccharides. Pediatr. Infect. Dis. J. 11:677–681.

5. Baker, C. J., M. S. Edwards, and D. L. Kasper. 1981. Role of antibody to native type III polysaccharide of group B *Streptococcus* in infant infection. Pediatrics 68:544–549.

6. Bardardottir, E., S. Jonsson, I. Jonsdottir, A. Sigufsson, and H. H. Marsson. 1990. IgG subclass response and opsonization of *Streptococcus pneumoniae* against vaccination of healthy adults. J. Infect. Dis. 162:482–488.

7. Barret, D. J., and E. M. Ayoub. 1986. IgG subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 65:127–134.

8. Berezn, E. N., E. S. Carvalho, S. Casagrande, M. C. Brandileone, I. M. Mimica, and C. K. Farhat. 1996. *Streptococcus pneumoniae* penicillin-non-susceptible strains in invasive infections in São Paulo, Brazil. Pediatr. Infect. Dis. J. 15:1051–1053.

9. Black, C. M., B. D. Plikaytis, T. W. Wells, R. M. Ramirez, G. M. Carline, B. A. Chilimonczyk, and C. A. Reimer. 1988. Two-site immunoenzymometric assays for serum IgG subclass infant/maternal ratios at full term. J. Immunol. Methods 106:71–81.

10. Brandileone, M. C., V. S. Vieira, S. T. Casagrande, R. C. Zanella, M. L. Guerra, S. Bokerman, J. C. De Moraes, E. R. Baldacici, C. B. Chamone, M. A. Oliveira, D. G. De Matos, T. M. Arruda, M. F. Coelho, S. M. D’Avila, A. R. dos Santos, and J. L. Di Fabbio. 1997. Prevalence of serotypes and anti-influenzal resistance of *Streptococcus pneumoniae* strains isolated from Brazilian children with invasive infections. Microb. Drug Resist. 3:141–146.

11. Brandileone, M. C., V. S. Vieira, R. C. Zanella, I. M. Landgraf, C. E. A. Helle, E. De Escragnole Taunay, J. C. Moraes, and R. Austrian. 1995. Distribution of serotypes of *Streptococcus pneumoniae* isolated from invasive infections over a 16-year period in the greater São Paulo area, Brazil. J. Clin. Microbiol. 33:2799–2791.

12. Capurro, H. L., S. Konichezky, D. Fonseca, and R. Caldeyro-Barcia. 1978. Simplified method for diagnosis of gestational age in the newborn infant. J. Pediatr. 93:128–122.

13. Chudwin, D. S., D. Wara, G. Schiffman, S. G. Artrip, and J. A. Ammann. 1985. Maternal-fetal transfer of pneumococcal capsular polysaccharide antibodies. Am. J. Dis. Child. 139:378–380.

14. Costa-Carvalho, B. T., H. M. Vieira, B. R. R. Dimantas, C. Arslanian, C. K. Nasplty, D. Sole, and M. M. S. Carneiro-Sampaio. 1996. Transfer of IgG subclasses across the placenta in term and preterm pregnancies. Braz. J. Med. Biol. Res. 29:201–204.

15. Dogan, R., D. Englehard, and E. Piccard. 1992. Epidemiology of invasive pneumococcal infections in Israel. JAMA 268:3328–3332.

16. Elborn, M. S., D. M. Grange, H. Nahn, A. Quinn, and P. G. Schackelford. 1987. Concentrations of antibodies in paired maternal and infant sera: relationship to IgG subclass. J. Pediatr. 111:783–788.

17. Englund, J. A., P. Geven, C. Thompson, R. Anwaruddin, C. S. Turner, and G. R. Silver. 1997. Haemophilus influenzae type-b-specific antibody in infants after maternal immunization. Pediatr. Infect. Dis. J. 16:1122–1130.

18. Eskola, J., A. K. Tabaka, E. Kela, E. Pekkanen, R. Kallikoski, and M. Leinonen. 1992. Epidemiology of invasive pneumococcal infections in children in Finland. JAMA 268:3323–3327.

19. Freij, A., L. Hammarstrom, M. Persson, and C. Smith. 1984. Plasma pneumococcal antibody of the IgG1 class and subclasses in otitis prone children. Clin. Exp. Immunol. 56:235–238.

20. French, M., and G. Harrison. 1984. Serum IgG subclass concentration in healthy adults: a study using monoclonal antisera. Clin. Exp. Immunol. 56:473–475.

21. Grunebaum, A. M., H. Minoff, R. Schwartz, and G. Schiffman. 1986. Pneumococcal polysaccharide antibody levels in patients with term and preterm pregnancies. Obstet. Gynecol. 68:483–487.

22. Halsey, J. F. (IBT Reference Laboratory). Personal communication.

23. Hay, F. C., M. G. R. Hull, and G. Torrigiano. 1971. The transfer of human IgG subclasses from mother to foetus. Clin. Exp. Immunol. 9:355–358.

24. Inostroza, J., O. Trucco, V. Prado, A. M. Vinet, G. Retamal, G. Ossa, R. R. Facklam, and R. U. Sorensen. 1998. Capsular type and antibiotic resistance of *Streptococcus pneumoniae* isolated in two Chilean cities. Clin. Diagn. Lab. Immunol. 5:176–180.

25. Kaniuk, A. S. C., J. E. Lorain, and M. A. Monteil. 1992. Specific IgG subclass antibody levels and phagocytosis of serotype 14 pneumococcus following immunization. Scand. J. Immunol. 36:596–598.

26. Koskela, M. 1987. Serum antibodies to pneumococcal C polysaccharide in children. Response to acute pneumococcal otitis media or to vaccination. Pediatr. Infect. Dis. J. 6:519–526.
26. Kristensen, K., A. Ghys, B. Lausen, T. Bardington, and C. Heilmann. 1996. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr. Infect. Dis. J. 15:525–529.

27. Kurikka, S., R. M. Olander, J. Eskola, and H. Kayhty. 1996. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy. Pediatr. Infect. Dis. J. 15:530–535.

28. Lagos, R., I. Horwitz, J. Toro, O. San Martin, P. Abrego, C. Bustamante, S. S. Wasserman, O. S. Levine, and M. M. Levine. 1996. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr. Infect. Dis. J. 15:216–222.

29. Landesman, S. H., and G. Schiffman. 1981. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev. Infect. Dis. 3:5184–5197.

30. Lawrence, E. M., K. M. Edwards, G. Schiffmann, J. M. Thompson, W. K. Vaughn, and P. F. Wright. 1983. Pneumococcal vaccine in normal children. Am. J. Dis. Child. 137:646–650.

31. Leach, A., S. J. Ceesay, W. A. S. Banya, and B. M. Greenwood. 1996. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr. Infect. Dis. J. 15:333–339.

32. Letson, C. W., M. Santosham, R. Reid, C. Priehs, B. Burns, A. Jahnke, S. Shahid, N. S., M. C. Steinhoff, S. S. Hoque, T. Begum, C. Thompson, and G. R. Schiff. 1996. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine during pregnancy. Vaccine 14:963–970.

33. Lim, P. L., and Y. L. Lau. 1993. Occurrence of IgG subclass antibodies to ovalbumin, avidin, and pneumococcal polysaccharide in children. Int. Arch. Allergy Appl. Immunol. 104:137–143.

34. Lortan, J. E., A. Kaniuk, and M. A. Montei. 1993. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin. Exp. Immunol. 91:54–57.

35. McNabh, T., T. Y. Koh, K. J. Dormington, and R. H. Painter. 1976. Binding of IgG and fragments to placental membrane preparations. J. Immunol. 117:882–888.

36. Morell, A., W. D. Terry, and T. A. Waldmann. 1970. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49:673–680.

37. Mushler, D. M., A. J. Chapman, A. Gorre, S. Jonsson, D. Briles, and R. E. Baughn. 1986. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154:245–256.

38. O’Dempsey, T. J., T. McArdle, S. J. Ceesay, W. A. Banya, E. Demba, O. Secka, M. Leinonen, and H. Kayhty. 1996. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 14:963–970.

39. Pichichero, M. E., M. A. Shelly, and J. J. Treanor. 1997. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr. Infect. Dis. J. 16:72–74.

40. Quaata, S. A. C., S. L. J. Kirch, D. C. Quakenbush, S. Phipps, C. O. Strohmeyer, J. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590–592.

41. Robbins, C. B., R. Austrian, C. J. Lee, S. C. Rastogi, G. Schiffman, J. Henrikson, P. H. Makela, C. V. Broume, R. R. Facklam, R. H. Tiesjema, and J. C. Parke. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136–1159.

42. Romero-Steiner, S., R. U. Sorensen, M. F. Schinsky, L. Leiva, P. Giangrosso, A. L. Fenner, and G. M. Carluone. 1998. Immune responses to pneumococcal CRM197-hepta-valent polysaccharide conjugate vaccine in children who responded poorly to the 23-valent polysaccharide vaccine, abstr. P1-4, p. 76. In Programs and Abstracts of the International Conference on Emerging Infectious Diseases.

43. Schiff, R. I. 1986. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev. Infect. Dis. 8S449–8S56.

44. Sessegolo, J. F., A. S. S. Levin, C. E. Levy, M. Asensi, R. R. Facklam, and L. Martins Teixeira. 1994. Distribution of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated in Brazil from 1988 to 1992. J. Clin. Microbiol. 32:906–911.

45. Shahid, N. S., M. C. Steinhoff, S. S. Hoque, T. Begum, C. Thompson, and G. R. Schiff. 1995. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet 346:1252–1257.

46. Siber, G. R., P. H. Schur, A. C. Aisenberg, S. A. Weitzman, and G. Schiffman. 1980. Correlation between serum IgG-2 concentration and the antibody response to bacterial polysaccharide antigens. N. Engl. J. Med. 303:178–182.

47. Sniadak, D. H., B. Schwartz, H. Liptman, J. Bogaerts, J. C. Butler, R. Dagan, G. Echaniz-Aviles, N. Lloyd-Evans, A. Fenoli, N. I. Girgis, J. Henriksen, K. Klugman, D. Lehmann, A. K. Tahala, J. Vandepitte, S. Gove, and R. F. Breiman. 1995. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children—implications for vaccine strategies. Pediatr. Infect. Dis. J. 14:503–510.

48. Taunay, A. E., R. Austrian, I. M. Landgraf, M. E. P. Vieira, and C. E. A. Melles. 1990. Sorotipos de Streptococcus pneumoniae isolados de liquido cefalorraquidiano no periodo de 1977–1988 na cidade de Sao Paulo, Brasil. Rev. Inst. Med. Trop. Sao Paulo 32:11–15.